Autor/Autorin: Baba Shahid Mudasir
I Dr. Shahid M. Baba was born in Srinagar, Kashmir, India. I studied in Kashmir at the leading tertiary care hospital Sher-i-Kasmir Institute of Medical Sciences (SKIMS), Soura, where i successfully completed three degrees: B.Sc in Medical Lab Technology, MSc in Immunology & Molecular Medicine and Ph.D in Immunology & Molecular Medicine on May 2017
The aims of this book was to gather insights and investigate the factors influencing the response of Acute Promyelocytic Leukemia patients to conventional chemotherapy. Monitoring the response to APL therapy is a continuum that begins at diagnosis and carries on serially throughout the entire course of treatment. This is the first study from the valley of Kashmir (North India) on Acute Promyelocytic Leukemia so far in terms of following up on the disease. Our study confirmed karyotyping using peripheral blood as an analyte is a key determinant in overall disease outcome, successful remission induction, relapse risk and overall survival. We also reported promoter hypermethylation status of p15 gene as a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL. This opens up a new vista for other researchers to carry out further research into the disease in order to find out how relevant or otherwise the observations and technique would be for future use.
Über den Autor
I Dr. Shahid M. Baba was born in Srinagar, Kashmir, India. I studied in Kashmir at the leading tertiary care hospital Sher-i-Kasmir Institute of Medical Sciences (SKIMS), Soura, where i successfully completed three degrees: B.Sc in Medical Lab Technology, MSc in Immunology & Molecular Medicine and Ph.D in Immunology & Molecular Medicine on May 2017
Klappentext
The aims of this book was to gather insights and investigate the factors influencing the response of Acute Promyelocytic Leukemia patients to conventional chemotherapy. Monitoring the response to APL therapy is a continuum that begins at diagnosis and carries on serially throughout the entire course of treatment. This is the first study from the valley of Kashmir (North India) on Acute Promyelocytic Leukemia so far in terms of following up on the disease. Our study confirmed karyotyping using peripheral blood as an analyte is a key determinant in overall disease outcome, successful remission induction, relapse risk and overall survival. We also reported promoter hypermethylation status of p15 gene as a prospective prognostic indicator and a reliable clinical aid in assessment of patients with APL. This opens up a new vista for other researchers to carry out further research into the disease in order to find out how relevant or otherwise the observations and technique would be for future use.
